Completed PHASE1 INTERVENTIONAL 6-arm NCT03988413

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Ascending Trial of SYHA1402 Tablets in Healthy Subjects

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Diabetic Neuropathy Peripheral

Interventions 100mg 200mg 25mg 400mg 50mg 800mg

Updated 5 times since 2019 Last updated: Apr 28, 2020 Started: Aug 5, 2019 Primary completion: Jan 14, 2020 Completion: Jan 14, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetic Neuropathy Peripheral and is currently completed. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jul 2019 — May 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China